Specialty pharmaceutical company SteadyMed Ltd. has filled an application requesting orphan drug designation for its lead medical product, an investigational therapy to treat pulmonary arterial hypertension (PAH) called Trevyent. The application has been acknowledged by the U.S. Food and Drug Administration (FDA) and…
News
Tuesday, May 5th was World Pulmonary Hypertension Day, and to mark the occasion Team PHenomenal Hope, a cycling team comprised of medical and endurance professionals, shared with the PH community how to help raise awareness about pulmonary hypertension. Team PHenomenal Hope has been a highly effective advocate for the disease…
The Pulmonary Hypertension Association (PHA) has shared the results of its recent National Call-In Day, reporting that the event was a major success thanks to the participation of the pulmonary hypertension community. The National Call-In Day took place on April 16th as part of an initiative to encourage PH advocates to call Congressional members and…
The Pulmonary Hypertension Association (PHA) has awarded 12 community activists with the 2015 Tom Lantos Innovation in Community Service Award. The awardees, who will receive $5,000 each, are heading projects that are committed to raising awareness about pulmonary hypertension (PH). The Tom Lantos Innovation in Community Service Awards were created…
The Pulmonary Hypertension Association (PHA) recently announced in a press release that it will take the lead in a global effort to educate the general public about pulmonary hypertension on May 5, marked as World Pulmonary Hypertension Day. Pulmonary hypertension (PH) is a rare, debilitating, life-threatening condition characterized by an increase of blood…
The Pulmonary Hypertension Association (PHA) has granted the PHA-accredited Center of Comprehensive Care (CCC) designation to the Pulmonary Hypertension Center at Rhode Island Hospital, making it one of the first centers of its type to receive the status in the country. The accreditation is given to centers for their excellency in…
Ascendis Pharma A/S, a clinical stage biotechnology company focused on creating drug candidates by improving existing drugs, recently announced results from its Phase 1 single ascending dose trial of TransCon Treprostinil, which produced a dose-dependent increase in plasma treprostinil levels. However, results from the study showed that the tolerability of treprostinil…
Findings from a recent study published in the Annals of Cardiac Anaesthesia determined that a multidisciplinary approach is key to the successful management of pregnant patients with Pulmonary Hypertension (PH). According to the study, secondary PH results in higher morbidity and mortality, and in particular the…
Researchers at the University of Glasgow and Glasgow Caledonian University in the United Kingdom published in the journal Cardiovascular Research findings revealing that that a specific receptor of the hormone estrogen is involved in the development of pulmonary hypertension. The findings may offer new insights into why…
According to a new paper, “Pulmonary hypertension and hepatic cirrhosis,” published in the Spanish-language journal, Revista Clinica Espanola, pulmonary hypertension (PH) occurs frequently in people with hepatic cirrhosis. There are various ways in which hepatic cirrhosis can be caused by PH, but the most common occurrence is something…
A new study led by researchers at Chengdu Women’s and Children’s Central Hospital in China revealed that angiotensin II interferes with the expression of collagen and specific proteins important in pulmonary hypertension pathology, suggesting a potential new therapeutic target. The study was published in the journal Genetics and…
Long-term results for the GRIPHON trial are in. According to a presentation made at the 35th Annual International Society for Heart and Lung Transplantation (ISHLT) Meeting & Scientific Sessions, selexipag (otherwise known as Uptravi® from Actelion) effectively treats patients with pulmonary arterial…
